Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-BRIDGING: EVT +/- IV Thrombolysis in Extended Window Stroke
NCT05634382Phase 3Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator and tenecteplase in ischemic stroke (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Good clinical outcome at 90 days. Status: unknown.
02
Drugs
tissue-plasminogen activatortenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05634382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634382.